BAP1 and Histone Deacetylase Expression in Uveal Melanoma V1
Research type
Research Study
Full title
BAP1 and Histone Deacetylase Expression in Uveal Melanoma
IRAS ID
169440
Contact name
Sarah Coupland
Contact email
Sponsor organisation
University of Liverpool
Duration of Study in the UK
2 years, 4 months, 27 days
Research summary
Determining the levels of a factor known as BAP1, which is believed to suppress progression of a rare eye cancer known as uveal melanoma (UM), can inform the prognosis of those suffering from the disease. That is, low BAP1 levels correlate with a high risk of metastasis and poor prognosis. BAP1 levels have also been positively correlated with factors known as histone deacetylases (HDACs) that modify DNA. The interplay between these proteins in UM cells may play a role in regulating metastasis. Assessing the levels of BAP1 and HDACs in UM cells, and how these correlate with one another, will provide the basis for further investigation into their role in metastasis in UM with the ultimate goal of identifying whether they can be targeted therapeutically.
REC name
South West - Central Bristol Research Ethics Committee
REC reference
16/SW/0112
Date of REC Opinion
18 Apr 2016
REC opinion
Favourable Opinion